Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
Medtronic
McKesson
AstraZeneca

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,816,404

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,816,404 protect, and when does it expire?

Patent 7,816,404 protects TRIFERIC and is included in two NDAs.

This patent has eleven patent family members in ten countries.

Summary for Patent: 7,816,404
Title:Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
Abstract: A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts.
Inventor(s): McCall, Jr.; William S. (Raleigh, NC)
Assignee: Rockwell Medical Technologies, Inc. (Wixom, MI)
Application Number:12/138,018
Patent Claim Types:
see list of patent claims
Composition; Process; Use; Dosage form;

Drugs Protected by US Patent 7,816,404

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate FOR SOLUTION;INTRAVENOUS 208551-001 Apr 25, 2016 RX Yes Yes   Start Trial   Start Trial METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT   Start Trial
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate SOLUTION;INTRAVENOUS 206317-001 Jan 23, 2015 RX Yes Yes   Start Trial   Start Trial Y METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,816,404

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 554754   Start Trial
Canada 2638081   Start Trial
Cyprus 1113903   Start Trial
Denmark 2016940   Start Trial
European Patent Office 2016940   Start Trial
Spain 2383713   Start Trial
Croatia P20120416   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Baxter
Moodys
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.